Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
River Stone Biotech Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner working within 1 distinct art unit. The concentrated nature of this portfolio suggests a highly specific focus for the company's current patent activities. Because there is only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is centralized. This allows for a singular focus on the preferences of this specific examiner within the Biotechnology & Pharmaceuticals sector.
NOLAN, JASON MICHAEL is the busiest examiner for this portfolio, handling 1 pending office action. This 1 pending action represents the entirety of the company's current workload at the office. Practitioners can focus their strategy on this individual examiner's specific tendencies and requirements. The lack of diversity in art units or examiners means that the outcome of this 1 action will significantly impact the current state of the portfolio. This centralized approach simplifies the management of the company's intellectual property but increases the importance of each interaction with the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18452054 | Demethylation of Reticuline and Derivatives Thereof with Fungal Cytochrome P450 | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Aug 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRiver Stone Biotech Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jason Michael Nolan has the most, with 1 of River Stone Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
